Inflammatory Bowel Disease (IBD)

Immunology
1
Pipeline Programs
3
Companies
3
Clinical Trials
1 recruiting
0
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
1
0
0
0
0
0
Early DiscoveryClinical DevelopmentMarket

Competitive Landscape

3 companies ranked by most advanced pipeline stage

Parvus Therapeutics
Parvus TherapeuticsCA - South SF
1 program
1
PVT401Phase 11 trial
Active Trials
NCT07423000Not Yet RecruitingEst. Nov 2027
EXACT Therapeutics
EXACT TherapeuticsNorway - Oslo
1 program
Detection of Advanced Colorectal Neoplasia by Stool DNA in Inflammatory Bowel DiseaseN/A1 trial
Active Trials
NCT01819766Completed440Est. Jan 2017
Takeda
TakedaTOKYO, Japan
1 program
TapptN/A1 trial
Active Trials
NCT06750731Recruiting200Est. Sep 2026

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
2027
Parvus TherapeuticsPVT401
TakedaTappt
EXACT TherapeuticsDetection of Advanced Colorectal Neoplasia by Stool DNA in Inflammatory Bowel Disease

Clinical Trials (3)

Total enrollment: 640 patients across 3 trials

A Phase 1 Study of PVT401 in Healthy Subjects

Start: Apr 2026Est. completion: Nov 2027
Phase 1Not Yet Recruiting

Study of Efficacy and Adherence to Subcutaneous vs. Intravenous Vedolizumab in Patients With Inflammatory Bowel Disease Using a Novel Remote MONITORing Intervention

Start: May 2025Est. completion: Sep 2026200 patients
N/ARecruiting
NCT01819766EXACT TherapeuticsDetection of Advanced Colorectal Neoplasia by Stool DNA in Inflammatory Bowel Disease

Detection of Advanced Colorectal Neoplasia by Stool DNA in Inflammatory Bowel Disease

Start: Mar 2013Est. completion: Jan 2017440 patients
N/ACompleted

Related Jobs in Immunology

Phase Legend

PreclinicalLab & animal studies
Phase 1Safety & dosing
Phase 2Efficacy testing
Phase 3Large-scale trials
On MarketApproved & available

Key Insights

1 actively recruiting trials targeting 640 patients
3 companies competing in this space